Complaint challenges the American Society of Anesthesiologists for promoting biased, analytically misguided studies in its journal, on its website, and through CME activity PARSIPPANY, N.J., April 14, ...

PARSIPPANY, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that full results its Phase 4 study of EXPAREL® (bupivacaine liposome injectable suspension) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results from its second pivotal, Phase 3 clinical trial assessing the safety and efficacy of EXPAREL ® ...

Data From Two-Year Follow-up Study Assessing EXPAREL Safety in Breast Augmentation Surgery Using Silicone Implant Also Presented DENVER and PARSIPPANY, N.J., Sept. 26, 2011 /PRNewswire via COMTEX/ -- ...

PARSIPPANY, N.J., Dec 05, 2013 (BUSINESS WIRE) -- Pacira Pharmaceuticals, Inc. PCRX +1.03% today announced that it has submitted a Prior Approval Supplement (PAS) with the U.S. Food and Drug ...

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the Phase 3 clinical trial assessing the safety and efficacy of EXPAREL(R) (bupivacaine liposome injectable suspension) in femoral nerve ...

PARSIPPANY, N.J., Jan 09, 2012 (BUSINESS WIRE) -- Pacira Pharmaceuticals, Inc. today provided updated timing for its commercial launch of EXPAREL(R) (bupivacaine liposome injectable suspension), a non ...

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira Pharmaceuticals, Inc. (NAS: PCRX) today announced findings from the completed first part of its Phase 2/3 clinical trial assessing the use and administration ...

Results Presented at the 2015 Annual Meeting of the American Academy of Orthopedic Surgeons Find Overall Hospital Cost Savings of More Than $1.5 Million Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) ...